Search

Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity treatments continue to improve. The Food and Drug Administration said Friday that drugmaker Novo Nordisk can meet present and future demand in the U.S. But patients may still see some limited supply disruptions as the drugs move from the manufacturer to distributors and then pharmacies. The injectable drugs have been in shortage since 2022. In December, the FDA declared that the shortages of treatments Zepbound and Mounjaro from another drugmaker, Eli Lilly and Co., also had been resolved.

A new poll from The Associated Press-NORC Center for Public Affairs Research shows about half of U.S. adults believe it is a good thing for adults to use weight-loss drugs like Ozempic, Wegovy and other brands if they are struggling with obesity or have a health condition tied to weight. But Americans are not as supportive of teens who have obesity using the medications. The AP-NORC poll results indicate that even as doctors urge the drugs’ use, some Americans continue to have concerns about weight-loss drugs, particularly for people who aren’t struggling with obesity.